deltatrials
Terminated EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01707823

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer

Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin

Sponsor: National Cancer Institute (NCI)

Conditions Adenocarcinoma of the Lung Recurrent Non-small Cell Lung Cancer Stage IA Non-small Cell Lung Cancer Stage IB Non-small Cell Lung Cancer Stage IIA Non-small Cell Lung Cancer Stage IIB Non-small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer
Interventions acetylsalicylic acid laboratory biomarker analysis
Updated 10 times since 2017 Last updated: Jan 10, 2020 Started: Oct 31, 2012 Primary completion: Jun 30, 2018 Completion: Aug 31, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Funding unavailable

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

A EARLY_PHASE1 clinical study on Adenocarcinoma of the Lung and Recurrent Non-small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 10 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotRecruiting~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshotSuspended~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshotActive Not Recruiting~Jan 2019 – ~Feb 2020 · 13 months · monthly snapshotActive Not Recruiting~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated EARLY_PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated EARLY_PHASE1

  4. Feb 2020 — Jan 2021 [monthly]

    Terminated EARLY_PHASE1

    Status: Active Not Recruiting → Terminated

  5. Jan 2019 — Feb 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Phase: NA → EARLY_PHASE1

▶ Show 5 earlier versions

  1. Sep 2018 — Jan 2019 [monthly]

    Active Not Recruiting NA

    Status: Suspended → Active Not Recruiting

  2. Jul 2018 — Sep 2018 [monthly]

    Suspended NA

    Status: Recruiting → Suspended

  3. Jun 2018 — Jul 2018 [monthly]

    Recruiting NA

  4. Feb 2017 — Jun 2018 [monthly]

    Recruiting NA

  5. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Vanderbilt-Ingram Cancer Center
Data source: Vanderbilt-Ingram Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations